Dr. Reddy’s Labs Drops On Repeat Observations For Duvvada Plant – Shares of the Hyderabad-based drug maker fell as much as 2.61 percent to Rs 2,389 after it received eight observations, five of them a repeat of 2017 and warning letter of 2015, from the U.S. drug regulator at its Duvvada facility—crucial for future growth prospects in its largest market.
The observations were issued after an audit of the injectable plant starting Oct. 23. BloombergQuint has obtained a copy of the form 483 issued by the U.S. Food and Drug Administration to India’s fifth-largest pharma company by sales.
